EN
Ngā Kāwai katoa
EN

News

Q&A for Sinocare SARS-CoV-2 Antibody Test Strip

Time: 2020-05-08 Ngā Taunga: 158

1. Me pehea te tautuhi i nga keehi kua whakaarohia?

Whakatutukihia nga keehi me tetahi o nga taunakitanga e rua o muri mai ranei:

a. Ko te tino waipiro RT-PCR e whakaatu ana mo te waikawa koronavirus hou;

pē b. Ko te raupapa ira Viral he tino homologous ki te mohio ki te coronavirus hou

c. Ko te IgM me te IgG tino huaketo e kitea ana i te serum; IgP huaketo motuhake IgG he

ka kitea, ka tae atu ranei ki te tangohanga o te pikinga ki te 4-piara i te waa o te tupono ka whakaritea ki te waahanga o te waikawa

 

2. He aha te pai mehemea ka puta aku hua pai?

If you have a positive test result, it is very likely that you have vIrus. Therefore, it is also likely that you may be placed in isolation to avoid spreading the virus to others. However, due to unknown source interference substances, the test result may still be positive which is called false-positive. Your healthcare provider will work with you to determine how best to care for you based on the test results along with other factors of your medical history, and your symptoms, possible exposures, and geographic location of places you have recently traveled.

 

3. He aha te pai mena ka puta aku hua kino?

A negative test result means that the antibody that caused by vIrus was not found in your sample. For vIrus, a negative test result for a sample collected while a person has symptoms usually means that vIrus did not cause your recent illness.

However, it is possible for this test to give a negative result that is incorrect (false negative) in some people with vIrus. This means that you could possibly still have vIrus even though the test is negative. If this is the case, your healthcare provider will consider the test result together with all other aspects of your medical history (such as symptoms, possible exposures, and geographical location of places you have recently traveled) in deciding how to care for you. It is important that you work with your healthcare provider to help you understand the next steps you should take.

 

4. He aha me whakamahi ahau i tenei hua?

I tenei wa, ko te tikanga whaimana e tino whakamahia ana ko te whakamatautau waikawa nukura, engari ko tenei tikanga kua whakapumautia kaore e kitea he hunga mate huakita katoa, ina koa ko te whakamatautau i te nuinga o te waa kei te whakamahi i nga tauira o te haehae o runga. Mo nga keehi kua whakaarohia, i etahi wa ka nui nga whakamatautau me nga whakamatautau maha me nga tauira maha ka whiwhi hua pai. Ana hoki he take kaore e taea e nga tira whakapae te whakapae pai ki nga whakamatautau waikawa ngota. E wha nga take pea:

1) the viral loads in upper respiratory tract samples are much lower than that in lower respiratory tract samples in vIrus tūroro

2) ko te tuku i nga tini mate o nga turoro i nga waahanga rereketanga o te mate ka rere ke ki te whānuitanga whanui;

3) ko te kohinga o te huringa paipa-kounga teitei ka hiahia nga kaimahi hauora;

4) Ko nga reera PCR mai i nga puna rereke he maha nga rereke.

Ko nga take i runga ake nei he wero nui ki te whakarato i te maimoatanga tautoko-te wa tika me te aukati arai. Na reira, he mea tino nui te kitenga serological.

 

The specific clinical significance and value of serological detection for vIrus area follows:

1) for the suspected case of the first doctors' office visiting and the confirmed case with the clinical diagnosis but without viral nucleic acid testing, the positive results of antibody can be used as an aid in the diagnosis of vIrus;

2) mo nga hononga piri pai me nga hua pai o te antibody, me whai waahi ki te kawe kawenga, te whakawhānui ake i te waa kitenga mo te waatea, te whakapai ake i te waa whakamate waikawa o te waikawa, te whakanui ake i nga momo tauira mo te whakamatautau waikawa nukura, me te mahi tirotiro tata;

3) patients tested by viral nucleic acid, serum antibody positive result indicates that specific immune response has been induced in body, which can help doctors to judge the connection between the body's immunity and the subsequent development of the patient's disease;

4) i whakamahia mo te aromatawai nui o nga taumata o te antibody serum i roto i nga turoro o te mate, i roto i te tikanga ka taea te whakamahi i te plasma antibody titer tiketike mo te maimoatanga o nga turoro tino;

5) combine with viral nucleic acid testing to identify potential virus carriers in key populations, such as travelers in outbreak countries or regions, participants in important meetings or events, and people returning to work or school. Isolate and monitoring the people with virus nucleic acid negative but antibody positive, in order to detect potential vIrus infection in time, reduce the transmission risk.